Searchable abstracts of presentations at key conferences in endocrinology

ea0024op1.3 | (1) | BSPED2010

Intensive insulin therapy in adolescent type 2 diabetes

White B , Hindmarsh P C , Viner R M

Background: Glucolipotoxicity contributes to declining B-cell function and acceleration of type 2 diabetes (T2DM). Intensive insulin therapy has been shown to rapidly reverse glucolipotoxicity and improve B-cell function, particularly if given soon after diagnosis. Recent trials in adults have shown promise, with 50% in remission at 1 year after intensive insulin therapy.Methods: We report 4 cases of young people with T2DM treated with intravenous insuli...

ea0024bc1.1 | (1) | BSPED2010

Investigation of premature adrenarche reveals a high incidence of congenital adrenal hyperplasia (CAH)

Kosta K , Gkourogianni A , Alatzoglou K S , Hindmarsh P C , Dattani M T

Background: Premature pubic hair development, with or without manifestations of androgen production, is a common clinical presentation. Premature adrenarche (PA) needs to be differentially diagnosed from congenital adrenal hyperplasia (CAH) and may be associated with early development of puberty.Aim: To study the characteristics at presentation, endocrine profile and outcome of patients who presented with premature pubic hair development. We studied retr...

ea0024p59 | (1) | BSPED2010

An unusual spectrum of phenotype in autoimmune polyendocrinopathy syndrome type 1: a case series of 5 patients within a single centre

Dias R P , Hakeem V , Peters C , Baker J , Hindmarsh P C , Dattani M T

Introduction: The Autoimmune Polyendocrinopathy Syndromes (APS) comprise 4 clinical subtypes (1–4), APS type 1 is an autosomal recessive disorder caused by mutations in the AIRE (Autoimmune Regulator) gene. It should include at least 2 of the following 3 major criteria: chronic mucocutaneous candidiasis (CMC), hypoparathyroidism (HPT) and adrenal insufficiency (AI) although 50% of patients develop all 3 features, usually before the age of 20 years. In addition, there are ...

ea0024p19 | (1) | BSPED2010

Outcome of rhGH treatment in patients with achondroplasia and skeletal dysplasias

Alatzoglou K S , Mohan R , Ward S , Bridges N , Brook C G D , Hindmarsh P C , Dattani M T

Background and aim: Achondroplasia (ACH) is one of the commonest skeletal dysplasias affecting 1:15 000–1:40 000 live births. The average attained adult height is 131±5.6 cm for men and 124±5.9 cm for women. Previous studies have shown that the use of rhGH may result in transient increase in the growth rate, but there have been no long-term data regarding adult height. We aimed to study a cohort of patients with ACH and other skeletal dysplasias who have been tr...